News

Psious has announced the closing of a 8 million Euros financing round, co-led by Caixa Capital Risc and Asabys Partners

With this round the company will complete the development of its virtual reality solutions for the treatment of anxiety disorders (phobias, panic, post-traumatic stress disorder, obsessive-compulsive disorder), stress management, depression, attention problems such as ADHD, and autism or psychotic spectrum disorders, among many others. To this end, the company is focusing its activities on consolidating clinical activity through international studies that analyze the therapeutic effect of virtual reality in the field of cognitive-behavioral therapy.

| Read more |

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

| Read more |

Competitive Intelligence Startup Kompyte Raises $3M and Expands Operations in Austin, Texas

Caixa Capital Risc, Adara Ventures and Swanlaab Venture Factory, along with other existing investors are the funders.
The company provides revolutionary software that automates competitive research and reporting, so their customers can monitor competitors in real-time and adjust their strategy to best compete.

| Read more |

Sheetgo closes a round led by Caixa Capital Risc to finance the launch of its new platform [Article in Spanish]

The start-up, specialized in creating workflows from spreadsheets, will launch its new platform. It already reaches half a million users online and captures one million dollars to keep growing.

| Read more |

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Mr. Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

| Read more |